Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

Video

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Ramez N. Eskander, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Elias Jabbour, MD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Related Content
Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, Moores Cancer Center, the University of California, San Diego Health

Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer

April 25th 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet — Copenhagen University Hospital

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
Oliver Dorigo, MD, PhD

Early Data for CRX100 Pave Way for Potential Combinations in Recurrent, Platinum-Resistant Ovarian Cancer

April 22nd 2024
Article
Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024
Article